CA3020333A1 - Formulations of abaloparatide, transdermal patches thereof, and uses thereof - Google Patents

Formulations of abaloparatide, transdermal patches thereof, and uses thereof Download PDF

Info

Publication number
CA3020333A1
CA3020333A1 CA3020333A CA3020333A CA3020333A1 CA 3020333 A1 CA3020333 A1 CA 3020333A1 CA 3020333 A CA3020333 A CA 3020333A CA 3020333 A CA3020333 A CA 3020333A CA 3020333 A1 CA3020333 A1 CA 3020333A1
Authority
CA
Canada
Prior art keywords
abaloparatide
transdermal patch
transdermal
administration
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3020333A
Other languages
English (en)
French (fr)
Inventor
Gary Hattersley
Alan Harris
Jamal SAEH
Ehab Hamed
Kenneth Brown
Daniel Dohmeier
Joan Moseman
Ying Zhang
Lisa Dick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kindeva Drug Delivery LP
Original Assignee
3M Innovative Properties Co
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/056196 external-priority patent/WO2017062922A1/en
Application filed by 3M Innovative Properties Co, Radius Health Inc filed Critical 3M Innovative Properties Co
Publication of CA3020333A1 publication Critical patent/CA3020333A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3020333A 2016-04-18 2017-04-06 Formulations of abaloparatide, transdermal patches thereof, and uses thereof Pending CA3020333A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662324336P 2016-04-18 2016-04-18
US62/324,336 2016-04-18
US201662353249P 2016-06-22 2016-06-22
US62/353,249 2016-06-22
US201662396196P 2016-09-18 2016-09-18
US62/396,196 2016-09-18
PCT/US2016/056196 WO2017062922A1 (en) 2015-10-09 2016-10-08 Formulations of pthrp analogues, transdermal patches thereof, and uses thereof
USPCT/US2016/056196 2016-10-08
US201762479250P 2017-03-30 2017-03-30
US62/479,250 2017-03-30
PCT/US2017/026462 WO2017184355A1 (en) 2016-04-18 2017-04-06 Formulations of abaloparatide, transdermal patches thereof, and uses thereof

Publications (1)

Publication Number Publication Date
CA3020333A1 true CA3020333A1 (en) 2017-10-26

Family

ID=60116311

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3020333A Pending CA3020333A1 (en) 2016-04-18 2017-04-06 Formulations of abaloparatide, transdermal patches thereof, and uses thereof

Country Status (7)

Country Link
US (3) US10568937B2 (enExample)
EP (2) EP3481414B1 (enExample)
JP (4) JP6920341B2 (enExample)
AU (2) AU2017253674B2 (enExample)
CA (1) CA3020333A1 (enExample)
ES (1) ES2904891T3 (enExample)
WO (1) WO2017184355A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3020333A1 (en) 2016-04-18 2017-10-26 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
US10996208B2 (en) * 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
KR20210134324A (ko) * 2019-02-28 2021-11-09 라디우스 헬쓰, 인코포레이티드 아발로파라티드의 전달을 위한 경피 시스템 및 사용 방법
CN110917243B (zh) * 2019-12-30 2021-06-04 南京晓庄学院 一种含植物提取物的凝胶膏剂及其制备方法
WO2021149012A1 (en) 2020-01-24 2021-07-29 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
WO2022149066A1 (en) * 2021-01-05 2022-07-14 Radius Health, Inc. Treatment of long bone fractures with abaloparatide
US12023156B2 (en) 2021-10-13 2024-07-02 Satio, Inc. Dermal patch for collecting a physiological sample
US11452474B1 (en) 2021-04-14 2022-09-27 Satio, Inc. Dual lever dermal patch system
US12178979B2 (en) 2021-10-13 2024-12-31 Satio, Inc. Dermal patch for delivering a pharmaceutical
US12053284B2 (en) 2021-11-08 2024-08-06 Satio, Inc. Dermal patch for collecting a physiological sample
US12214346B2 (en) 2021-10-13 2025-02-04 Satio, Inc. Dermal patch with a diagnostic test strip
US11964121B2 (en) 2021-10-13 2024-04-23 Satio, Inc. Mono dose dermal patch for pharmaceutical delivery
US11877848B2 (en) 2021-11-08 2024-01-23 Satio, Inc. Dermal patch for collecting a physiological sample
US12048543B2 (en) 2021-11-08 2024-07-30 Satio, Inc. Dermal patch for collecting a physiological sample with removable vial
WO2023281447A1 (en) 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event
WO2024246840A1 (en) * 2023-06-01 2024-12-05 Radius Health, Inc. Methods for identification and quantitation of abaloparatide and related peptide impurities
CN119113134B (zh) * 2024-09-13 2025-05-16 南京羚诺生物医药技术研究院有限公司 一种提升阿巴帕肽半衰期的制备方法及其在治疗骨质疏松症中的用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
CA2302255C (en) 1997-09-09 2011-11-08 F. Hoffmann-La Roche Ag Fracture healing using pthrp analogs
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
GB0017999D0 (en) 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
EP1333880B1 (en) 2000-10-26 2009-04-15 Alza Corporation Transdermal drug delivery devices having coated microprotrusions
ES2333849T3 (es) 2001-04-20 2010-03-02 Alza Corporation Disposicion de microsalientes que presenta un revestimiento que contiene un agente beneficioso.
US6881203B2 (en) 2001-09-05 2005-04-19 3M Innovative Properties Company Microneedle arrays and methods of manufacturing the same
EP1476178A4 (en) * 2002-02-14 2009-08-26 Bayer Pharmaceuticals Corp FORMULATION STRATEGIES IN STABILIZING PEPTIDES IN ORGANIC SOLVENTS AND DRY CONDITIONS
EP1513547A4 (en) 2002-05-23 2009-11-04 Michael F Holick USE OF PEPTIDE ANALOGUES OF PARATHYROID HORMONE FOR THE TREATMENT OF VAGINAL ATROPHY
EP1523367A1 (en) 2002-07-19 2005-04-20 3M Innovative Properties Company Microneedle devices and microneedle delivery apparatus
BRPI0412029A (pt) * 2003-06-30 2006-09-05 Alza Corp formulações para microprojeções revestidas contendo contra-ìons não-voláteis
WO2005014034A1 (en) * 2003-07-14 2005-02-17 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
JP2007503268A (ja) 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾化合物の送達
JP5007427B2 (ja) 2004-05-13 2012-08-22 アルザ コーポレイション 副甲状腺ホルモン剤の経皮送達のための装置および方法
JP5015787B2 (ja) 2004-11-18 2012-08-29 スリーエム イノベイティブ プロパティズ カンパニー マイクロニードルアレイの接触コーティング法
US20070270341A1 (en) 2005-09-06 2007-11-22 Paul Morley Parathyroid hormone analogues and methods of use
JP2009522288A (ja) 2005-12-28 2009-06-11 アルザ コーポレイション 安定な治療剤形
CN101466393A (zh) 2006-03-15 2009-06-24 阿尔扎公司 用于经皮递送甲状旁腺激素药剂以治疗骨质减少的方法
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
CA2664734C (en) 2006-10-03 2023-08-01 Radius Health, Inc. Method of drug delivery for bone anabolic protein
US20090016935A1 (en) * 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
CN102016389B (zh) * 2008-05-16 2012-10-31 夏普株式会社 背光源单元和液晶显示装置
KR20110086854A (ko) 2008-11-18 2011-08-01 쓰리엠 이노베이티브 프로퍼티즈 컴파니 중공 마이크로니들 어레이 및 방법
JP2012523270A (ja) 2009-04-10 2012-10-04 スリーエム イノベイティブ プロパティズ カンパニー 中空マイクロニードルアレイを製造する方法並びにそれに由来する製品及びその使用法
WO2011075569A1 (en) 2009-12-18 2011-06-23 3M Innovative Properties Company Molding thermotropic liquid crystalline polymers and articles made therefrom
KR101728194B1 (ko) 2010-02-24 2017-05-02 히사미쓰 세이야꾸 가부시키가이샤 마이크로 니들 디바이스 및 그 제조 방법
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
WO2012119004A2 (en) * 2011-03-01 2012-09-07 Sloan-Kettering Institute For Cancer Research Parathyroid hormone analogs, compositions and uses thereof
SG194570A1 (en) * 2011-04-22 2013-12-30 Radius Health Inc Method of drug delivery for pth, pthrp and related peptides
AU2012345768B2 (en) * 2011-11-30 2016-05-12 Kindeva Drug Delivery L.P. Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
US9581438B2 (en) 2012-12-31 2017-02-28 General Electric Company Systems and methods for control of a non-destructive testing system
KR101866005B1 (ko) 2013-02-13 2018-06-08 히사미쓰 세이야꾸 가부시키가이샤 마이크로 니들 코팅용 조성물 및 마이크로 니들 디바이스
CN105555353B (zh) 2013-09-18 2019-01-01 考司美德制药株式会社 一种微针贴应用装置以及一种贴支架
ES2630106T3 (es) * 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
WO2016141250A1 (en) 2015-03-03 2016-09-09 Radius Health, Inc. USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
BR112018007159A2 (pt) 2015-10-09 2018-11-06 3M Innovative Properties Co formulações de análogos de pthrp, emplastros transdérmicos dos mesmos e usos dos mesmos
ES2909043T3 (es) 2015-10-09 2022-05-05 Kindeva Drug Delivery Lp Composiciones de zinc para sistemas de microagujas recubiertos
CA3020333A1 (en) 2016-04-18 2017-10-26 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof

Also Published As

Publication number Publication date
JP6919087B2 (ja) 2021-08-11
JP2021113209A (ja) 2021-08-05
EP3481414B1 (en) 2021-11-03
AU2021204233A1 (en) 2021-07-15
AU2017253674B2 (en) 2021-07-29
US10568937B2 (en) 2020-02-25
JP2022171769A (ja) 2022-11-11
JP2021175744A (ja) 2021-11-04
AU2021204233B2 (en) 2023-07-13
JP2019511558A (ja) 2019-04-25
AU2017253674A1 (en) 2018-10-25
WO2017184355A1 (en) 2017-10-26
US10980862B2 (en) 2021-04-20
US20190117739A1 (en) 2019-04-25
EP3998061A1 (en) 2022-05-18
US20200164045A1 (en) 2020-05-28
EP3481414A1 (en) 2019-05-15
ES2904891T3 (es) 2022-04-06
JP6920341B2 (ja) 2021-08-18
EP3481414A4 (en) 2020-05-13
US20210369816A1 (en) 2021-12-02
JP7139498B2 (ja) 2022-09-20

Similar Documents

Publication Publication Date Title
AU2021204233B2 (en) Formulations of abaloparatide, transdermal patches thereof, and uses thereof
CA3000533C (en) Formulations of pthrp analogues, transdermal patches thereof, and uses thereof
US20230277444A1 (en) FORMULATIONS OF PTHrP ANALOGUES, TRANSDERMAL PATCHES THEREOF, AND USES THEREOF
WO2011139838A2 (en) Intranasal formulations
CA3122239A1 (en) Transdermal system for the delivery of abaloparatide and method of use
HK40072671A (en) Formulations of abaloparatide, transdermal patches thereof, and uses thereof
HK40008968B (en) Formulations of abaloparatide, transdermal patches thereof, and uses thereof
HK40064524A (en) Formulations of pthrp analogues, transdermal patches thereof, and uses thereof
HK1260883A1 (zh) Pthrp类似物的制剂、其透皮贴剂及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220310